The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Safety & tolerability of canakinumab by measuring the maintenance of response over time using the Investigators Clinical Assessment of Disease Activity scale and the evaluation of serum inflammation markers CRP (C-Reactive Protein), SAA (Serum Amyloid A. [ Time Frame: 18 months ]
Secondary Outcome Measures
Change in long term maintenance of Health-Related Quality of Life and productivity measured from baseline to end of study. [ Time Frame: Baseline, 18 months ]
Treatment adherence with canakinumab for the duration of the study. [ Time Frame: 18 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
4 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female patients at least 4 years of age at the time of the screening visit
Patient's informed consent for > or = 18 years of age before any assessment is performed
Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients < 18 years of age.
Patients with a diagnosis of CAPS: FCAS/FCU, MWS, or NOMID/CINCA
Body weight > or = 15 kg
Able to communicate with the investigator and comply with the requirements of the study (for children the parent can assist when necessary)
Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at baseline
Patient of childbearing potential (man or woman) and unwilling to use double barrier method of contraception. It is required that double barrier method of contraception be used (i.e. condom with spermicide or diaphragm with spermicide) by patients of childbearing potential (man or woman) regardless of whether a hormonal agent is also used as a method of contraception.
Participation in any clinical investigation within 4 weeks prior to dosing
Live vaccinations within 3 months prior to the start of the trial, during the trial and up to 3 months following the last dose.
History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial (this can be discussed with Novartis on a case by case basis in case of uncertainty).
History of drug or alcohol abuse within 12 months prior to dosing
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
"Other protocol-defined inclusion/exclusion criteria may apply"